Adding a drug called evolocumab to cholesterol-lowering statins can lower the chances of serious heart problems by 20% in people who already have heart disease.
Evidence from Studies
Supporting (3)
Community contributions welcome
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
The study shows that adding evolocumab to statins cuts the risk of heart attacks, strokes, and heart-related deaths by 20%, just like the claim says.
Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis
The study found that adding evolocumab to statins lowers the risk of serious heart problems, which supports the general idea in the claim, though the benefit was slightly less than 20%.
Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events
The study looked at adding drugs like evolocumab to statins and found they lower heart problem risks by about 19%, which is almost exactly what the claim says.
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.